- Short Communication
- Published:
Design, synthesis, and biological evaluation of resveratrol derivatives as PPARα agonists
Journal of the Korean Society for Applied Biological Chemistry volume 56, pages 353–356 (2013)
Abstract
The peroxisome proliferator-activated receptor subtype α (PPARα) was established as a molecular target in drug discovery research for new lipid-lowering drugs. Pterostilbene is a naturally occurring PPARα agonist that has been shown to lower plasma lipid concentrations via the activation of PPARα. In this study, various pterostilbene conjugates with methyl, amino acid, and pivaloxymethyl (POM) groups at the 4-OH position were synthesized, and the activating effect on PPARα were investigated. Of the conjugates investigated, 4-OMe-pterostilbene had lower activating effect than pterostilbene, but the pterostilbenes with either amino acid (4a and 4b) or POM moiety (5) showed a small but significant increase in PPARα activation of PPARα activity compared to pterostilbene. Therefore, the structure-activity relationship of the pterostilbene conjugates studied indicates that substitution of the free 4-OH moiety of pterostilbene with a nonmethyl group can increase PPARα agonistic activity. This finding warrants further investigation of the structure-activity relationship of the pterostilbene conjugates as potent PPARα agonists.
References
Cho M, Lee WS, Hong J, Park S, Moon D, Paik S et al. (2005) 5-(3,5-Di-tertbutyl-4-hydroxybenzylidene) thiazolidine-2,4-dione modulates peroxisome proliferators-activated receptor γ in 3T3-L1 adipocytes: Roles as a PPARγ ligand. Mol Cell Endocrinol 242, 96–102.
Desai RC, Metzger E, Santini C, Meinke PT, Heck JV, Berger JP et al. (2006) Design and synthesis of potent and subtype-selective PPARalpha agonists. Bioorg Med Chem Lett 16, 1673–1678.
Kim MK, Park K, Yeo W, Choo H, and Chong Y (2009) In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg Med Chem 17, 1164–1171.
Kim MK, Park K, Lee C, Park HR, Choo H, and Chong Y (2010) Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoiety. J Med Chem 53, 8597–8607.
Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble C et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94, 4318–4323.
Pettit GR, Grealish MP, Jung MK, Hamel E, Pettit RK, Chapuis JC et al. (2002) Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem 45, 2534–2542.
Rimando AM, Nagmani R, Feller DR, and Yokoyama W (2005) Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem 53, 3403–3407.
Wilson TM and Wahli W (1997) Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1, 235–241.
Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ et al. (1999) Molecular recognition of fatty acids by peroxisome proliferatoractivated receptors. Mol Cell 3, 397–403.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, M.K., Chong, Y. Design, synthesis, and biological evaluation of resveratrol derivatives as PPARα agonists. J Korean Soc Appl Biol Chem 56, 353–356 (2013). https://doi.org/10.1007/s13765-013-3086-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13765-013-3086-9